Tag Archives: large pharma

Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases

5 Jul

A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.

The firm invests in therapeutics, and in this sector the firm is interested in both early and late stage assets. The firm will consider any type of therapeutic technology (including small molecules, large molecules and gene therapies), and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases, CNS diseases and primary care indications (such as influenza) will not be considered. Drug-device combinations will also be considered.

The firm prefers to work with companies who have opened dialogue with the FDA. The firm considers a high-quality management team to be a significant requirement of their investment criteria. It is preferred that assets can reach the marketplace 3-5 years post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI Panel Announcement: Large Pharma Firms Looking Externally For New Assets

7 Apr

By Christine A. Wu, Research Analyst, LSN


Large pharma companies are increasingly looking to early stage companies to fill their future pipelines. These firms have a variety of means of engaging with early stage companies, including in-licensing, collaborations, equity investments, and M&A. At RESI@TMCx, four senior external sourcing staff from the pharma world will explain what their firms are looking for, how they work with early stage companies, and how an emerging biotech company can position themselves to make a big pharma deal.

Moderated by Bill Kohlbrenner, CSO, Life Science Nation, the panelists are:

  • Marc Schwabish, US Head, Pharma Business Development & Licensing, Bayer
  • Barbara Araneo, Innovation Sourcing Director, Novo Nordisk
  • Joseph Simeone, Director, Business Development & Licensing, Merck
  • Mark Day, Executive Director, Head of External Research & Scouting, Alexion


%d bloggers like this: